Price T Rowe Associates Inc Humanigen, Inc Transaction History

Price T Rowe Associates Inc

  • $836 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.81 - $3.97 $18,224 - $39,973
-10,069 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$3.66 - $8.22 $2,020 - $4,537
-552 Reduced 5.2%
10,069 $37,000
Q3 2021

Nov 15, 2021
SELL
$5.93 - $17.83 $593 - $1,782
-100 Reduced 0.93%
10,621 $63,000
Q2 2021

Aug 16, 2021
BUY
$13.54 - $22.74 $145,162 - $243,795
10,721 New
10,721 $186,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email